Status:
COMPLETED
Staccato Loxapine Pulmonary Safety in Patients With COPD
Lead Sponsor:
Alexza Pharmaceuticals, Inc.
Conditions:
Chronic Obstructive Pulmonary Disease
Eligibility:
All Genders
40-65 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to assess the pulmonary safety of 2 doses of Staccato Loxapine within a day in patients with COPD.
Detailed Description
To address the possibility that inhalation of loxapine may have adverse pulmonary effects, we studied two 10-mg inhaled doses of loxapine or placebo were given 10 hr apart to subjects with chronic obs...
Eligibility Criteria
Inclusion
- History of COPD for at least 6 months with pre-bronchodilator FEV1 ≥40% of predicted value and \>15 pack-year history of cigarette smoking.
Exclusion
- History of asthma, or any other acute or chronic pulmonary disease.
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2009
Estimated Enrollment :
53 Patients enrolled
Trial Details
Trial ID
NCT00889837
Start Date
June 1 2009
End Date
August 1 2009
Last Update
March 14 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Spartanburg Medical Research
Spartanburg, South Carolina, United States, 29303